MarketCap
Facebook
X
Telegram
Meridian Bioscience Balance Sheet 2022-2007 | VIVO
Brief overview of Meridian Bioscience's assets and capital
This overview follows the five latest available annual observations between 2015 and 2019.
Assets advanced +77.6% to $325.5 million from $183.3 million; annual growth near 15.4% reflects a fast increase in scale.
Asset growth of +77.6% came with a +672.7% rise in liabilities. Financial leverage became more prominent.
The equity-to-assets ratio is 58.7%, compared with 90.5% five periods ago. The balance sheet has a substantial internal cushion.
The net-debt-to-equity ratio is 0.07x. Balance sheet leverage is low on this measure.
Cash represents 19.2% of assets versus 27.3% initially, showing how the immediate liquidity reserve changed.
Retained earnings are $63.1 million versus $51.1 million initially. The direction shows how results contributed to equity.
Overall picture
Meridian Bioscience's balance sheet is broadly resilient, though selected areas require monitoring. The balance between assets, equity and liabilities remains the key issue.
Annual Balance Sheet Meridian Bioscience
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-54.6 M | 12.2 M | 17.1 M | 13.4 M | -9.58 M | -2.42 M | 11.1 M | -50 M | -43 M | -44.3 M | -31.6 M | -23.6 M | - | - | - | - |
Long Term Debt |
25 M | 60 M | 68.8 M | 75.8 M | 44.9 M | 50.1 M | 54.6 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1.83 M | 1.99 M | 1.79 M | - | 5.25 M | 4.5 M | 3.75 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
37.1 M | 74.3 M | 105 M | 114 M | 51.8 M | 57.3 M | 63 M | 2.16 M | 2.16 M | 2.09 M | 171 K | 1.7 M | - | - | - | - |
Total Current Liabilities |
58 M | 47.2 M | 52.5 M | 20.9 M | 24.2 M | 22.9 M | 22.6 M | 15.3 M | 13.7 M | 19.6 M | 18.5 M | 15.3 M | 14.5 M | 16.8 M | - | - |
Total Liabilities |
- | - | - | 135 M | 76 M | 80.2 M | 85.4 M | 17.4 M | 15.9 M | 21.7 M | 18.6 M | 17 M | - | - | - | - |
Retained Earnings |
223 M | 181 M | 109 M | 63.1 M | 49.5 M | 46.9 M | 49.6 M | 51.1 M | 48.9 M | 46.9 M | 40.2 M | 38.1 M | 42.2 M | 45.5 M | - | - |
Total Assets |
463 M | 450 M | 405 M | 325 M | 251 M | 250 M | 252 M | 183 M | 177 M | 177 M | 161 M | 155 M | 155 M | 156 M | - | - |
Cash and Cash Equivalents |
81.5 M | 49.8 M | 53.5 M | 62.4 M | 59.8 M | 57.1 M | 47.2 M | 50 M | 43 M | 44.3 M | 31.6 M | 23.6 M | 37.9 M | 54 M | 49.3 M | 49.4 M |
Book Value |
463 M | 450 M | 405 M | 191 M | 175 M | 170 M | 167 M | 166 M | 161 M | 155 M | 143 M | 139 M | 155 M | 156 M | - | - |
Total Shareholders Equity |
368 M | 328 M | 248 M | 191 M | 175 M | 170 M | 166 M | 166 M | 161 M | 155 M | 143 M | 139 M | 137 M | 138 M | 128 M | 113 M |
All numbers in USD currency
Quarterly Balance Sheet Meridian Bioscience
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
25 M | 25 M | 25 M | 25 M | 50 M | 50 M | 50 M | 50 M | 58.8 M | 58.8 M | 98.8 M | 48.8 M | 75.8 M | 75.8 M | 75.8 M | 41.9 M | 43.4 M | 43.4 M | 46.4 M | 47.9 M | 49 M | 49 M | 51.3 M | 52.4 M | 53.5 M | 53.5 M | 55.7 M | 56.8 M | 54.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
37.6 M | 37.6 M | 40 M | 40.7 M | 63.5 M | 63.5 M | 87.7 M | 79.4 M | 91.2 M | 91.2 M | 143 M | 76.7 M | 106 M | 106 M | 114 M | 48.2 M | 50.5 M | 50.5 M | 54.4 M | 54.4 M | 55.6 M | 55.6 M | 57.6 M | 61.2 M | 63.3 M | 63.3 M | 65.8 M | 67.2 M | 2.13 M | 2.13 M | 2.1 M | 1.99 M | 2.04 M | 2.04 M | 2.16 M | 2.16 M | 2.16 M | - | 2.09 M | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
193 M | 193 M | 217 M | 225 M | 196 M | 196 M | 174 M | 162 M | 136 M | 136 M | 103 M | 75.3 M | 65.9 M | 65.9 M | 59 M | 54.1 M | 52.3 M | 52.3 M | 49.5 M | 47.9 M | 47.9 M | 47.9 M | 46.5 M | 51.5 M | 47.5 M | 47.5 M | 52.6 M | 52.2 M | 51.5 M | 51.5 M | 50.9 M | 50.2 M | 48.4 M | 48.4 M | 49 M | 48.4 M | 46.4 M | 46.4 M | 45.6 M | 43.3 M | 33 M | 33 M | 39.4 M | 38.7 M | 36.8 M | 36.8 M | 39.1 M | 40 M | 40.5 M | 44.6 M |
Total Assets |
457 M | 457 M | 466 M | 472 M | 459 M | 459 M | 447 M | 439 M | 424 M | 424 M | 420 M | 319 M | 338 M | 338 M | 322 M | 254 M | 250 M | 250 M | 254 M | 255 M | 252 M | 252 M | 245 M | 252 M | 250 M | 250 M | 255 M | 258 M | 186 M | 186 M | 179 M | 178 M | 177 M | 177 M | 179 M | 178 M | 175 M | 175 M | 171 M | 166 M | 157 M | 157 M | 159 M | 158 M | 155 M | 155 M | 158 M | 157 M | 156 M | 149 M |
Cash and Cash Equivalents |
74.1 M | 74.1 M | 83.5 M | 76.5 M | 72.7 M | 72.7 M | 70 M | 63.4 M | 63.2 M | 63.2 M | 63.4 M | 49.6 M | 68.6 M | 68.6 M | 55.2 M | 66.1 M | 61.5 M | 61.5 M | 57.9 M | 56.4 M | 54.7 M | 54.7 M | 55.3 M | 54.7 M | 49.3 M | 49.3 M | 45.8 M | 48.9 M | 53.4 M | 53.4 M | 46 M | 42.7 M | 49.5 M | 49.5 M | 39.3 M | 38.2 M | 43.7 M | 43.7 M | 40.4 M | 38.6 M | 33.1 M | 33.1 M | 27.9 M | 24.3 M | 26.2 M | 26.2 M | 25.6 M | 28.4 M | 41.5 M | 58.2 M |
Book Value |
457 M | 457 M | 466 M | 472 M | 459 M | 459 M | 447 M | 439 M | 424 M | 424 M | 420 M | 319 M | 338 M | 338 M | 322 M | 254 M | 250 M | 250 M | 254 M | 255 M | 252 M | 252 M | 245 M | 252 M | 250 M | 250 M | 255 M | 258 M | 186 M | 186 M | 179 M | 178 M | 177 M | 177 M | 179 M | 178 M | 175 M | 175 M | 171 M | 166 M | 157 M | 157 M | 159 M | 158 M | 155 M | 155 M | 158 M | 157 M | 156 M | 149 M |
Total Shareholders Equity |
341 M | 341 M | 366 M | 375 M | 345 M | 345 M | 322 M | 309 M | 279 M | 279 M | 233 M | 205 M | 197 M | 197 M | 189 M | 182 M | 179 M | 179 M | 175 M | 174 M | 173 M | 173 M | 168 M | 171 M | 166 M | 166 M | 169 M | 170 M | 169 M | 169 M | 164 M | 161 M | 161 M | 161 M | 162 M | 160 M | 157 M | 157 M | 151 M | 148 M | 138 M | 138 M | 141 M | 141 M | 138 M | 138 M | 138 M | 138 M | 137 M | 137 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Meridian Bioscience, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Germany
Canada
Niderland
Britain
Israel
China
Australia
Irlanda
Schweiz
